Compare Stocks: ANL, ZLAB, BHVN, and ZBIO

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANL Adlai Nortye	$13.23 -0.4%	$11.26	$0.88 ▼ $17.25	$531.20M	1.06	222,349 shs	165,190 shs
BHVN Biohaven	$14.58 -0.5%	$14.02	$7.48 ▼ $18.57	$2.21B	1.26	1.82 million shs	1.38 million shs
ZBIO Zenas BioPharma	$31.99 -1.4%	$25.91	$13.50 ▼ $44.60	$2.05B	-1.03	718,339 shs	409,915 shs
ZLAB Zai Lab	$23.57 +1.1%	$18.88	$15.96 ▼ $36.77	$2.65B	0.78	723,595 shs	1.70 million shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANL Adlai Nortye	0.00%	+2.15%	+34.55%	+2.47%	+743.17%
BHVN Biohaven	0.00%	+8.72%	-5.94%	+61.97%	-0.34%
ZBIO Zenas BioPharma	0.00%	+3.15%	+12.84%	+58.97%	+121.67%
ZLAB Zai Lab	0.00%	+27.64%	+13.81%	+19.04%	-33.30%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANL Adlai Nortye	$13.23 -0.4%	$11.26	$0.88 ▼ $17.25	$531.20M	1.06	222,349 shs	165,190 shs
BHVN Biohaven	$14.58 -0.5%	$14.02	$7.48 ▼ $18.57	$2.21B	1.26	1.82 million shs	1.38 million shs
ZBIO Zenas BioPharma	$31.99 -1.4%	$25.91	$13.50 ▼ $44.60	$2.05B	-1.03	718,339 shs	409,915 shs
ZLAB Zai Lab	$23.57 +1.1%	$18.88	$15.96 ▼ $36.77	$2.65B	0.78	723,595 shs	1.70 million shs

The Best Nuclear Energy Stocks to Buy

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANL Adlai Nortye	0.00%	+2.15%	+34.55%	+2.47%	+743.17%
BHVN Biohaven	0.00%	+8.72%	-5.94%	+61.97%	-0.34%
ZBIO Zenas BioPharma	0.00%	+3.15%	+12.84%	+58.97%	+121.67%
ZLAB Zai Lab	0.00%	+27.64%	+13.81%	+19.04%	-33.30%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ANL Adlai Nortye	2.67	Moderate Buy	$24.25	83.30% Upside
BHVN Biohaven	2.67	Moderate Buy	$21.63	48.32% Upside
ZBIO Zenas BioPharma	2.56	Moderate Buy	$44.29	38.44% Upside
ZLAB Zai Lab	2.71	Moderate Buy	$40.20	70.56% Upside

Current Analyst Ratings Breakdown

Latest ANL, ZLAB, BHVN, and ZBIO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/7/2026	ZLAB Zai Lab	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$44.00 ➝ $45.00
7/29/2026	ZLAB Zai Lab	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/14/2026	ANL Adlai Nortye	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/14/2026	ZLAB Zai Lab	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/9/2026	ZBIO Zenas BioPharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/7/2026	ZLAB Zai Lab	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
6/29/2026	BHVN Biohaven	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$11.00
6/29/2026	BHVN Biohaven	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral ➝ Underperform	$12.00 ➝ $11.00
6/26/2026	ZLAB Zai Lab	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
6/26/2026	BHVN Biohaven	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
6/24/2026	ZBIO Zenas BioPharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)

(Data available from 8/10/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ANL Adlai Nortye	$5M	105.84	N/A	N/A	($0.21) per share	-63.00
BHVN Biohaven	N/A	N/A	N/A	N/A	$0.39 per share	N/A
ZBIO Zenas BioPharma	$10M	201.95	N/A	N/A	$4.51 per share	7.09
ZLAB Zai Lab	$460.16M	5.83	N/A	N/A	$6.39 per share	3.69

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ANL Adlai Nortye	-$35.53M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	8/10/2026 (Estimated)
BHVN Biohaven	-$738.82M	-$5.67	N/A	N/A	N/A	N/A	-866.46%	-137.99%	8/10/2026 (Estimated)
ZBIO Zenas BioPharma	-$377.74M	-$8.47	N/A	N/A	N/A	N/A	-99.99%	-58.06%	8/11/2026 (Estimated)
ZLAB Zai Lab	-$175.54M	-$1.71	N/A	N/A	N/A	-41.86%	-27.43%	-16.72%	N/A

Latest ANL, ZLAB, BHVN, and ZBIO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2026	Q2 2026	ZBIO Zenas BioPharma	-$1.12	N/A	N/A	N/A	$15.00 million	N/A
8/10/2026	Q2 2026	ANL Adlai Nortye	-$0.1340	N/A	N/A	N/A	$4.72 million	N/A
8/10/2026	Q2 2026	BHVN Biohaven	-$0.7610	-$0.78	-$0.0190	-$0.91	$0.49 million	N/A
8/6/2026	Q2 2026	ZLAB Zai Lab	-$0.6794	-$0.46	+$0.2194	-$0.50	$103.87 million	$106.31 million
6/30/2026	Q2 2026	ZLAB Zai Lab	N/A	-$0.50	N/A	-$0.50	N/A	$106.31 million
5/13/2026	Q1 2026	ZBIO Zenas BioPharma	-$1.4742	-$1.46	+$0.0142	-$1.46	$25.00 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ANL Adlai Nortye	N/A	N/A	N/A	N/A	N/A
BHVN Biohaven	N/A	N/A	N/A	N/A	N/A
ZBIO Zenas BioPharma	N/A	N/A	N/A	N/A	N/A
ZLAB Zai Lab	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ANL Adlai Nortye	N/A	0.65	0.65
BHVN Biohaven	1.87	7.41	7.41
ZBIO Zenas BioPharma	1.04	11.94	11.94
ZLAB Zai Lab	N/A	2.13	1.92

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ANL Adlai Nortye	35.21%
BHVN Biohaven	88.78%
ZBIO Zenas BioPharma	N/A
ZLAB Zai Lab	41.65%

Insider Ownership

Company	Insider Ownership
ANL Adlai Nortye	N/A
BHVN Biohaven	13.80%
ZBIO Zenas BioPharma	22.00%
ZLAB Zai Lab	4.88%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ANL Adlai Nortye	127	40.00 million	N/A	Not Optionable
BHVN Biohaven	239	150.56 million	129.78 million	Optionable
ZBIO Zenas BioPharma	N/A	63.13 million	49.24 million	N/A
ZLAB Zai Lab	1,784	113.78 million	108.23 million	Optionable

ANL, ZLAB, BHVN, and ZBIO Headlines

Recent News About These Companies

Is Zai Lab’s (ZLAB) Rising Loss on Softer Revenue Reframing Its Investment-Led Growth Story?

August 10 at 3:06 PM | finance.yahoo.com

Zai Lab (NASDAQ:ZLAB) Stock Price Up 14.5% on Strong Earnings

August 8 at 1:40 AM | americanbankingnews.com

Zai Lab Q2 Earnings Call Highlights

August 7 at 5:03 PM | marketbeat.com

Zai Lab (NASDAQ:ZLAB) Issues Earnings Results, Beats Estimates By $0.18 EPS

August 6, 2026 | marketbeat.com

Zai Lab Limited (ZLAB) Q2 2026 Earnings Call Transcript

August 6, 2026 | seekingalpha.com

Zai Lab Limited 2026 Q2 - Results - Earnings Call Presentation

August 6, 2026 | seekingalpha.com

Here's What Key Metrics Tell Us About Zai Lab Limited (ZLAB) Q2 Earnings

August 6, 2026 | zacks.com

Zai Lab (NASDAQ:ZLAB) Shares Up 14.5% on Strong Earnings

August 6, 2026 | marketbeat.com

Zai Lab Announces Second Quarter 2026 Financial Results and Recent Corporate Updates

August 6, 2026 | businesswire.com

Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Receives Average Rating of “Moderate Buy” from Analysts

August 4, 2026 | defenseworld.netD

Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Receives Average Recommendation of "Moderate Buy" from Analysts

August 4, 2026 | americanbankingnews.com

Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Receives Average Rating of "Moderate Buy" from Analysts

August 4, 2026 | marketbeat.com

U.S. FDA Grants Orphan Drug Designation to Zai Lab’s DLL3-Targeting ADC Zocilurtatug Pelitecan (Zoci) for the Treatment of Neuroendocrine Carcinomas (NECs)

August 3, 2026 | finance.yahoo.com

Zai Lab (ZLAB) to Post Quarterly Earnings on Thursday

July 30, 2026 | marketbeat.com

Zai Lab to Announce Second Quarter 2026 Financial Results and Recent Corporate Updates on August 6, 2026

July 22, 2026 | businesswire.com

Zai Lab (NASDAQ:ZLAB) Stock Price Up 7% - Still a Buy?

July 15, 2026 | marketbeat.com

Zai Lab (NASDAQ:ZLAB) Sees Unusually-High Trading Volume - Should You Buy?

July 13, 2026 | marketbeat.com

Zai Lab (NASDAQ:ZLAB) CEO Ying Du Sells 7,026 Shares

July 2, 2026 | insidertrades.com

Zai Lab Limited (ZLAB) Gains EMA Orphan Drug Designation for DLL3-Targeting Cancer Therapy

June 30, 2026 | finance.yahoo.com

Insider Selling: Zai Lab (NASDAQ:ZLAB) CFO Sells $39,529.44 in Stock

June 30, 2026 | insidertrades.com

Zai Lab (NASDAQ:ZLAB) Director William Lis Sells 7,040 Shares of Stock

June 25, 2026 | insidertrades.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

ANL, ZLAB, BHVN, and ZBIO Company Descriptions

Adlai Nortye NASDAQ:ANL

$13.23 -0.05 (-0.38%)

As of 04:00 PM Eastern

Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas. The company is also developing AN0025, a small molecule prostaglandin E receptor 4 antagonist to modulate the tumor microenvironment that is in a Phase Ib clinical trial for the treatment of recurrent non-small cell lung cancer and urothelial cancer after anti-PD-1/PD-L1 treatments, recurrent triple-negative breast cancer, microsatellite stable colorectal cancer, and cervical cancer after standard of care treatments; and AN4005, an oral small-molecule PD-L1 inhibitor, which is in Phase I clinical trial to induce and stabilize PD-L1 dimerization and thereby disrupt the interaction between PD-1 and PD-L1. Its preclinical candidates include AN8025, a multifunctional antibody as T cell and antigen-presenting cell modulator; AN1025, an oral small molecule degrader of ß-catenin; and AN9025, an oral small molecule pan-KRAS inhibitor. The company was founded in 2004 and is based in Grand Cayman, the Cayman Islands.

Biohaven NYSE:BHVN

$14.58 -0.08 (-0.55%)

As of 03:58 PM Eastern

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities. It also offers BHV-1300, a product candidate in Phase 1 clinical trials to treat rheumatoid arthritis; BHV-1310 for the treatment of generalized myasthenia gravis and acute exacerbations or flares; BHV-1400 to treat IgA Nephropathy; and BHV-1600 for the treatment of dilated cardiomyopathy. In addition, the company develops BHV-1100, a product candidate in Phase 1a/1b clinical trials for multiple myeloma patients; BHV-1510, a preclinical product that targets carcinomas; and BHV-1500 for Hodgkin's lymphoma. It has license, development, and commercialization agreements with Yale University, AstraZeneca, University of Connecticut, Artizan Biosciences Inc., Reliant Glycosciences LLC, Katholieke Universiteit Leuven, BMS, and Highlightll Pharmaceutical Co. Ltd. The company was formerly known as Biohaven Research Ltd and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.

Zenas BioPharma NASDAQ:ZBIO

$31.99 -0.44 (-1.36%)

As of 04:00 PM Eastern

Zenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company, which engages in the development and commercialization of transformative immunology-based therapies for patients. The company was founded by Lonnie O. Moulder Jr on November 12, 2019 and is headquartered in Waltham, MA.

Zai Lab NASDAQ:ZLAB

$23.57 +0.25 (+1.07%)

As of 04:00 PM Eastern

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT. The company was incorporated in 2013 and is headquartered in Shanghai, China.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ANL, ZLAB, BHVN, and ZBIO Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ANL, ZLAB, BHVN, and ZBIO Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ANL, ZLAB, BHVN, and ZBIO Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ANL, ZLAB, BHVN, and ZBIO Company Descriptions

Adlai Nortye NASDAQ:ANL

Biohaven NYSE:BHVN

Zenas BioPharma NASDAQ:ZBIO

Zai Lab NASDAQ:ZLAB

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ANL, ZLAB, BHVN, and ZBIO Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ANL, ZLAB, BHVN, and ZBIO Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ANL, ZLAB, BHVN, and ZBIO Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ANL, ZLAB, BHVN, and ZBIO Company Descriptions

Adlai Nortye NASDAQ:ANL

Biohaven NYSE:BHVN

Zenas BioPharma NASDAQ:ZBIO

Zai Lab NASDAQ:ZLAB

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools